In the planning of future intervention trials using chemopreventive agents against
lung cancer, it is critical to evaluate the effect on
biomarkers implicated specifically in lung
carcinogenesis. With the use of the H520 and H522 human
lung cancer cell lines, the present study showed that treatment with
selenium (in the form of
methylseleninic acid) inhibited cell growth, arrested cell cycle progression at G(1), and induced apoptosis as a late event. Because H520 cells were more sensitive to
selenium than H522 cells (IC(50) of MSA was 2.5 or 10 micro M for H520 or H522 cells, respectively, at 24 h), a panel of nine
cell cycle regulatory proteins known to be involved in G(1)-->S transition was assessed by Western analysis using whole cell lysate from H520 cells. These nine
proteins (DP1, cdc25A,
cyclin A,
cyclin B(1),
cyclin D(1), cdk1, cdk5, p21(WAF1), and GADD153) have been reported previously by our laboratory to be modulated by MSA in human breast and
prostate cancer cells. Our data showed that only four (DP1, cdc25A, p21(WAF1), and GADD153) of nine
biomarkers produced the expected changes
after treatment of
lung cancer cells with MSA. This finding raises the possibility that the molecular targets sensitive to
selenium modulation may be tissue specific. Thus, the selection of
selenium biomarkers for evaluation in an intervention trial must be based on empirical data derived from the
cancer cell type of interest.